{'52WeekChange': 0.40444446,
 'SandP52WeekChange': 0.0644362,
 'address1': '1200 Prospect Street',
 'address2': 'Suite 525',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 12.9,
 'askSize': 1400,
 'averageDailyVolume10Day': 1599400,
 'averageVolume': 1002188,
 'averageVolume10days': 1599400,
 'beta': None,
 'beta3Year': None,
 'bid': 12.69,
 'bidSize': 1100,
 'bookValue': 2.085,
 'category': None,
 'circulatingSupply': None,
 'city': 'La Jolla',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 12.97,
 'dayLow': 11.12,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': None,
 'enterpriseToRevenue': None,
 'enterpriseValue': 131021536,
 'exDividendDate': None,
 'exchange': 'NCM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 7.5337143,
 'fiftyTwoWeekHigh': 24.42,
 'fiftyTwoWeekLow': 2.2,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 5211467,
 'forwardEps': -0.86,
 'forwardPE': -14.697675,
 'fromCurrency': None,
 'fullTimeEmployees': 4,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.58233,
 'heldPercentInstitutions': 0.096,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/inmunebio.com',
 'longBusinessSummary': 'INmune Bio, Inc., a clinical-stage immunotherapy '
                        "company, focuses on reprogramming the patient's "
                        "innate immune system to treat cancer Alzheimer's "
                        'disease, and non-alcoholic steatohepatitis. The '
                        'company intends to develop and commercialize product '
                        'candidates to treat hematologic malignancies and '
                        'solid tumors. Its development programs include '
                        'INKmune, which focuses on treating women with relapse '
                        'refractory ovarian carcinoma and patients with high '
                        'risk myelodysplastic syndrome; INB03 that treats '
                        'patients with advanced cancers with elevated '
                        'biomarkers of inflammation in their blood; XPro1595 '
                        "for the treatment of Alzheimer's disease; and LivNate "
                        'to treat patients with non-alcoholic steatohepatitis. '
                        'The company has license agreements with Xencor, Inc.; '
                        'Immune Ventures, LLC; University of Pittsburg; and '
                        'University College London. INmune Bio, Inc. was '
                        'founded in 2015 and is headquartered in La Jolla, '
                        'California.',
 'longName': 'INmune Bio, Inc.',
 'market': 'us_market',
 'marketCap': 169698320,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_530336663',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -7847675,
 'nextFiscalYearEnd': 1640908800,
 'open': 11.66,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '858 964 3720',
 'previousClose': 12.15,
 'priceHint': 2,
 'priceToBook': 6.0623503,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 12.97,
 'regularMarketDayLow': 11.12,
 'regularMarketOpen': 11.66,
 'regularMarketPreviousClose': 12.15,
 'regularMarketPrice': 11.66,
 'regularMarketVolume': 896018,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 13425500,
 'sharesPercentSharesOut': 0.0027,
 'sharesShort': 29384,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 4963,
 'shortName': 'INmune Bio Inc.',
 'shortPercentOfFloat': 0.0062,
 'shortRatio': 0.67,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'INMB',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.739,
 'twoHundredDayAverage': 5.3420577,
 'volume': 896018,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.inmunebio.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '92037'}